Singapore-based life sciences ecosystem builder Esco Group is investing Rmb100 million ($15 million) into a new manufacturing and innovation complex in China, with the aim of serving the rapidly growing Chinese market and address unmet needs for Chinese patients.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
